Last reviewed · How we verify

Imiquimod Topical Cream 3.75%

Sun Pharmaceutical Industries, Inc. · Phase 1 active Small molecule

Imiquimod Topical Cream 3.75% is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc.. It is currently in Phase 1 development.

At a glance

Generic nameImiquimod Topical Cream 3.75%
SponsorSun Pharmaceutical Industries, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Imiquimod Topical Cream 3.75%

What is Imiquimod Topical Cream 3.75%?

Imiquimod Topical Cream 3.75% is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc..

Who makes Imiquimod Topical Cream 3.75%?

Imiquimod Topical Cream 3.75% is developed by Sun Pharmaceutical Industries, Inc. (see full Sun Pharmaceutical Industries, Inc. pipeline at /company/sun-pharmaceutical-industries-inc).

What development phase is Imiquimod Topical Cream 3.75% in?

Imiquimod Topical Cream 3.75% is in Phase 1.

Related